Jun 08, 2023 / 01:30PM GMT
Akash Tewari - Jefferies - Analyst
Good morning, everyone. Day two of our healthcare conference. I hope everyone's enjoying it. For those who don't know me, my name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies. And I have the pleasure of hosting the Cytokinetics management team. This is one of our topics as an analyst. But maybe Robert, I'll hand it off to you for some brief introductory comments and we'll get into Q&A.
Robert Blum - Cytokinetics, Incorporated. - President & CEO
Sure. So I'm Robert Blum, I'm the President and CEO of Cytokinetics. I'm joined by Andrew Carlos, who's our Chief Commercial Officer today.
And before we get into the Q&A, I'll just provide a high-level summary of what this year has in store for us. It has the makings of being a transformational year for the company as we're expecting readout of results from the pivotal clinical trial of aficamten, our next-in-class cardiac myosin inhibitors. It's the subject of a Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy.
Cytokinetics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers